From Sarah in response to my questions about the autoimmune program and Resverlogix/Zenith compounds:

"Zenith’s epigenetics drug development platform has the potential to impact multiple diseases with significant unmet medical need. We are focusing on the discovery and clinical development of novel small molecule BET inhibitors for the treatment of patients with defined cancers and other therapeutic indications, including autoimmune diseases.

The IP owned by each company is based on composition claims (chemical structure). The IP does not overlap or shift around between the two companies based on indications, and both companies have all rights to their own IP. Both companies have compounds with different characteristics, including BET inhibitors with different selectivity profiles. The field of BET bromodomain inhibition is still in its infancy and published data suggest that BETi might have clinical application in a wider range of indications. Both companies are interested in expanding their platforms based on the activity and properties of their own compounds."